SABCS Researchers Discuss丨Chemotherapy-Free Triple Combination for Advanced Triple-Positive Breast Cancer: HER2 Dual Antibody + CDK4/6i + Fulvestrant
Numerous studies have confirmed the therapeutic benefits of combining anti-HER2 therapy with endocrine treatment in patients with advanced triple-positive breast cancer (HR+/HER2+). With the enrichment of new endocrine targeting treatments and anti-HER2 treatment schemes in recent years, there has been exploration into other combination schemes, which are hopeful in providing more effective and less toxic "chemotherapy-free" combination treatments for such patients. At the recently held 46th San Antonio Breast Cancer Symposium (SABCS 2023), Professor Santiago Escrivá-de-Romani from the Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology in Spain reported a Phase 2a study using a novel HER2 dual-specific antibody (zanidatamab) combined with palbociclib and fulvestrant to treat advanced triple-positive breast cancer, achieving positive anti-tumor activity and good safety.